Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Tolerability Study of KM602 in Patients With Advanced Solid Tumors

NCT05766527 is registered in ClinicalTrials.gov with Xuanzhu Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05766527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05766527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Tolerability Study of KM602 in Patients With Advanced Solid Tumors
Lead sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2023
Completion date
December 31, 2026
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor